Premium
Cyclophosphamide’s addition in relapsed/refractory multiple myeloma patients with biochemical progression during lenalidomide‐dexamethasone treatment
Author(s) -
Cesini Laura,
Siniscalchi Agostina,
Grammatico Sara,
Andriani Alessandro,
Fiorini Alessia,
De Rosa Luca,
Za Tommaso,
Rago Angela,
Caravita Tommaso,
Petrucci Maria Teresa
Publication year - 2018
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13086
Subject(s) - medicine , lenalidomide , cyclophosphamide , dexamethasone , multiple myeloma , regimen , refractory (planetary science) , progression free survival , oncology , thalidomide , chemotherapy , surgery , gastroenterology , astrobiology , physics
Objective The aim of this study was to evaluate the addition of cyclophosphamide in relapsed‐refractory multiple myeloma patients ( RRMM ) who experienced biochemical relapse or progression without CRAB , during treatment with lenalidomide and dexamethasone (Rd), to slow down the progression in active relapse. Methods This analysis included 31 patients with RRMM treated with Rd who received cyclophosphamide ( CR d) at biochemical relapse. The CR d regimen was continued until disease progression. Results The median number of CR d cycles administered was 8 (range: 1‐35). A response was observed in 9 (29%) patients. After a median observation time of 11 months, the median overall survival ( OS ) from the beginning of CR d was 17.7 months. The median progression‐free survival ( PFS ) from the beginning of CR d was 13.1 months. Conclusion The addition of cyclophosphamide delays the progression in patients who present a biochemical relapse during Rd treatment. The response rate and the duration of PFS obtained with minimal toxicities and low costs induced us to setting up a randomized clinical trial.